Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?-Reference-Cited by-同舟云学术

Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?

Published:2016-07-01 Issue:4 Volume:31 Page:750-761
ISSN:1226-3303
Container-title:The Korean Journal of Internal Medicine
language:en
Short-container-title:Korean J Intern Med

Author:

Ji Young Sok,Lee Min Sung,Min Chang Wook,Park Seong Kyu,Kim Se Hyung,Yun Jina,Kim Hyun Jung,Kim Kyoung Ha,Kim Chan Kyu,Lee Kyu-Taek,Won Jong-Ho,Hong Dae Sik

Publisher

Korean Association of Internal Medicine

Link

http://kjim.org/upload/kjim-2015-234.pdf

Reference25 articles.

1. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial

2. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

4. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of latent class analysis in diagnosis of graft-versus-host disease by serum markers after allogeneic haematopoietic stem cell transplantation;Scientific Reports;2020-02-27

2. Role of thymoglobulin in matched sibling allogeneic hematopoietic stem cell transplantation with busulfan and fludarabine conditioning in myeloid malignanicies;Bone Marrow Transplantation;2017-10-30

3. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party;Journal of Hematology & Oncology;2017-01-24